NCT00930033已完成3 期
Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 452
- 试验地点
- 2
- 主要终点
- The primary endpoint is overall survival.
研究概览
简要总结
The study compare the standard treatment with nephrectomy + sunitinib to treatment with sunitinib alone without nephrectomy. This study will be the first trial on this competitive context
详细描述
The 2 previous studies on the impact of nephrectomy (EORTC, SWOG) in metastatic renal cell carcinoma have justified recommendation to initial nephrectomy for patients presenting with metastatic renal cell carcinoma. But these studies were performed at the time of immunotherapy.
The objective is Evaluation of the importance of nephrectomy in patients with metastatic renal cell carcinoma treated with sunitinib (AA) Arm A : Nephrectomy followed by Sunitinib Arm B : Sunitinib alone Sunitinib will be administrated orally daily for 4 weeks followed by a 2 week rest( schedule 4/2), 6 weeks are considered as a cycle The starting dose will be 50 mg daily with provision for dose reduction based on tolerability Patient will be treated until disease progression or unacceptable toxicity occurrence or withdraw.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age ≥ 18 years
- •ECOG Performance Status 0 - 1
- •Biopsy (primary tumour or metastases) confirming the diagnosis of clear cell carcinoma
- •Documented metastatic disease
- •Absence of prior systemic treatment for kidney cancer including AA
- •Tumour amenable to nephrectomy (partial or total) in the opinion of the patient's urologist. Patients presenting with an inferior vena cava thrombosis can be included.
- •Patients for which the indication of Sunitinib is considered according to the recommendations rules given by national health authorities of participating countries. The prescription of Sunitinib in the circumstances of the study is considered as a standard treatment.
- •Platelets > or = 100 x 109/L, haemoglobin >or = 9 g/dl, neutrophils >or = 1.5 x 109/L;
- •Bilirubin < or = 2 mg/dL, aspartate transaminase (ASAT) and alanine transaminase (ALAT)< or = 2.5 times the upper normal limit (UNL) or < or = 5 times UNL for patients with liver metastases
- •Patients of child bearing age should use contraceptive methods
- •Patient able to follow the procedures outlined in the protocol as far as the planning of visits and examinations are concerned.
- •Life expectancy ≥ 3 months
- •Written informed consent
- •Patient without brain metastases or with radiotherapy or surgery treated brain metastases without progression into 6 weeks and non treated by corticoid
- •Patient non treated by anticoagulants excepted HBPM
排除标准
- •Prior systemic treatment for kidney cancer (including Anti Angiogenic)
- •Bilateral kidney cancer
- •Pregnant or breast feeding women
- •Acute coronary syndrome or episode of myocardial infarction or severe or unstable angina within the last 6 months as well as severe diabetes with severe peripheral arteriopathy or deep phlebitis not treated with low molecular weight heparin or arterial thrombosis within the last 3 months
- •Patients being treated with antivitamin K with curative intent (please note that patients being treated with low molecular weight heparin can be included)
- •Medical, general or psychiatric difficulties which, in the opinion of the Investigator, would make it inappropriate for trial entry
- •Symptomatic or untreated brain metastases (patients with brain metastases that have been treated by radiotherapy or surgery and have stable disease within 6 weeks, and are not requiring treatment with corticosteroids can be included)
- •Previous history of gastric disease or malabsorption, syndrome compromising the absorption of Sunitinib
- •Experimental treatment within the 28 days preceding inclusion
- •Other cancer within the previous 5 years (except for insitu skin carcinoma and treated localised prostate cancer with undetectable PSA)
- •Patient has received treatment with IV biphosphonate
结局指标
主要结局
The primary endpoint is overall survival.
时间窗: starting at 4 months
次要结局
- Progression-Free Survival(Starting at 4 months)
- Objective Response (complete or partial) is evaluated according to RECIST 1.1 criteria(Starting at 4 months)
- Clinical benefit (complete response, partial or stable for at least 12 weeks).(Starting at 4 months)
- Non-compliance to Sunitinib treatment is evaluated in arm A (nephrectomy + sunitinib) as the percentage of patients not starting sunitinib treatment within 6 weeks after nephrectomy(Starting at 4 months)
- Non-compliance to sunitinib treatment is evaluated in arm B (sunitinib alone) as the percentage of patients needing nephrectomy(Starting at 4 months)
- Post operative morbidity is evaluated as the percentage of deaths within 30 days following nephrectomy(Starting at 4 months)
研究者
研究点 (2)
Loading locations...
相似试验
终止
3 期
Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel ChemotherapyProstatic NeoplasmsNCT00676650Pfizer873
已完成
3 期
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination ChemotherapyStage IIIB Lung Non-Small Cell Cancer AJCC v7Stage IV Non-Small Cell Lung Cancer AJCC v7NCT00693992National Cancer Institute (NCI)210
已完成
1 期
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung CancerExtensive Stage Lung Small Cell CarcinomaRecurrent Lung Small Cell CarcinomaNCT00453154National Cancer Institute (NCI)156
Unknown
1 期
Sunitinib and Radiation in Patients With Resectable Soft-tissue SarcomaSoft Tissue SarcomaNCT00753727Australasian Sarcoma Study Group26
进行中（未招募）
1 期
A RANDOMIZED, PHASE 3 STUDY OF SUNITINIB IN COMBINATION WITH CAPECITABINE COMPARED WITH CAPECITABINE IN PATIENTS WITH PREVIOUSLY TREATED BREAST CANCERAdvanced/metastatic breast cancerMedDRA version: 8.1Level: LLTClassification code 10006279Term: Breast neoplasmEUCTR2006-004624-36-FRPfizer Inc.430